BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, December 9, 2025
Home » Blogs » BioWorld MedTech Perspectives » Getting in at the ground floor no longer viable for VCs

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

BioWorld MedTech

Getting in at the ground floor no longer viable for VCs

June 7, 2013
By Omar Ford

record imagesIn a recent conversation with one of my good friends who has been in the music industry off and on for 20+ years, I realized that there are some glaring similarities between that form of entertainment and med-tech.

Consider this quote from my friend if you will:

"Nowadays Omar, you have to create a buzz around yourself. You have to get people's attention and do most of the leg work yourself before a major label (distributor) will even look at you, or invest in you."
When he said this, I began thinking about how difficult it was to get funding now in Med-tech, and especially how some of the rugged veterans of med-tech have spoken openly about how meetings with venture capital firms have evolved.

In fact during one conference, a panelist described showing off a drawing of a device on a napkin to a VC firm and eventually getting support for the technology. Try doing that today he joked.

But the fact of the matter is, is that funding is trickier to get than it was in the past. Series A financings are really tough to secure to get, as VC firms are no longer looking to get in on the ground floor for some of these devices.

VC firms want tried and true proven evidence. It's even better if the company has approval for the device.

One could say this almost defeats the purpose and could possibly hinder innovation.

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 8, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 8, 2025.
  • 3D rendering of prion structure

    Epigenetic technology could eliminate misfolded prion proteins

    BioWorld Science
    The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
  • Novo Nordisk semaglutide pill

    CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

    BioWorld
    A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
  • IV drips

    ASH 2025: New blood cancer therapies trump chemo, older drugs

    BioWorld
    Targeted therapies and immunotherapies continue to show better results than chemotherapy in investigator-initiated and company-sponsored cancer trials, and newer...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing